(Q34660894)

3 August 2017

1 reference

title

Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry disease (English)

1 reference

enzyme replacement therapy

3 August 2017

main subject

0 references

1 reference

Michael Beck

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

Expert Opinion on Investigational Drugs

3 August 2017

published in

1 reference

3 August 2017

volume

11

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

851-858

1 reference

Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

The frequency of lysosomal storage diseases in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

Prevalence of lysosomal storage disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

Gabapentin therapy for pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

Patients with Fabry disease on dialysis in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

Quantitative analysis of cerebral vasculopathy in patients with Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

Selective arterial distribution of cerebral hyperperfusion in Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

Substrate reduction therapy for glycosphingolipid storage disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.6.851

10.1517/13543784.11.6.851

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference